Medication info
NARIGENTADUO Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

NARIGENTADUO Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
Oval sustained release tablet, white to nearly white, engraved with N501 on one side
Packaging
28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle
Approval status
Active

MFDS item code 202400607 · Approved 2024.03.22 · Insurance code 670105550

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes who are taking both linagliptin and metformin. It effectively helps manage blood sugar levels and improves the diabetic condition.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication is used to treat diabetes and helps control blood sugar levels. However, it can rarely cause a life-threatening condition called lactic acidosis, so caution is required. This medication should not be used if you have allergies to any of its ingredients, type 1 diabetes, severe kidney dysfunction, liver dysfunction, severe infections, or dehydration. It should also be avoided in cases of heart or respiratory diseases such as acute myocardial infarction, shock, or heart failure. Hypoglycemic symptoms may occur during treatment; therefore, careful monitoring of blood sugar changes is needed when used with other hypoglycemic agents. Elderly patients or those with unstable kidney function should have their kidney function regularly monitored, and dose adjustments may be necessary. This medication should be temporarily discontinued if acute kidney function deterioration is anticipated or when undergoing radiologic iodine contrast imaging tests. Swallow this medication whole without chewing or crushing; it may be seen in the stool but this is normal. If symptoms such as abdominal pain, severe muscle pain, weakness, or difficulty breathing occur, consult your doctor immediately. It is advisable to avoid using this medication during pregnancy or breastfeeding, and to consult a doctor if planning to become pregnant. This medication may lower vitamin B12 levels, so regular checks for vitamin B12 deficiency are necessary during prolonged use. Several drugs may interact with this medication; therefore, inform your doctor or pharmacist of any concurrent medications. In case of overdose, gastrointestinal disturbances and a risk of lactic acidosis may arise, so immediate medical treatment is essential. Lastly, keep this medication out of the reach of children and store it in a dry place.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbance
  • cough
  • loss of appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 147 more
  • abdominal pain
  • oral ulcers
  • liver function abnormalities
  • hepatitis
  • angioedema
  • urticaria
  • pruritus
  • erythema
  • rash
  • similar to pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reaction
  • angioedema
  • urticaria
  • abnormal vitamin B12 absorption test
  • angioedema
  • pruritus
  • rash
  • similar to pemphigus
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot syndrome
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • nausea
  • gastroesophageal reflux disease
  • gastritis
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • sensory impairment
  • chest discomfort
  • weakness
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • productive cough
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • muscle pain
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased triglycerides
  • decreased hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine phosphokinase
  • elevated ALT
  • androgenetic alopecia
  • hyperhidrosis
  • dermatitis
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • state of confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should ideally be maintained at room temperature between 1 and 30 degrees Celsius. Proper storage will help ensure the safety and effectiveness of the medication.

Appearance and packaging

Appearance

Oval sustained release tablet, white to nearly white, engraved with N501 on one side

Package unit

28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.